Eculizumab therapy on a patient with co‐existent lupus nephritis and C3 mutation‐related atypical haemolytic uremic syndrome: a case report
Abstract Background Thrombotic microangiopathy (TMA), a rare but serious complication of systemic lupus erythematosus (SLE), is associated with poor outcomes to conventional immunosuppressive therapy. Recently, eculizumab, a humanised monoclonal antibody that blocks the complement factor 5, has been...
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
BMC
2021-03-01
|
| سلاسل: | BMC Nephrology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12882-021-02293-2 |